4 / 12
Page 28
conferenceseries
.com
Volume 08
Journal of Alzheimers Disease & Parkinsonism
Parkinsons Congress 2018
May 14-15, 2018
May 14-15, 2018 Singapore
4
th
Global Experts Meeting on
Parkinson’s & Movement Disorders
Val66Met polymorphism in BDNF has no sexual and APOE ε4 status-based dimorphic effects on
susceptibility to alzheimer’s disease: Evidence from an updated meta-analysis of case-control studies
and high-throughput genotyping cohorts
Shan Jiang
Washington University, USA
S
ome studies showed that Val66Met polymorphism of Brain-Derived Neurotrophic Factor (BDNF) conveys susceptibility
to Alzheimer’s Disease (AD) in females only. However, the confounding effects of some risk factors for AD were omitted in
these studies. This meta-analysis comprising 19,604 AD patients and 26,333 controls was aimed to re-examine the association
between Val66Met and AD by conditioning the effects of age, sex and Àpolipoprotein E (APOE) ε4 status. In general, Val66Met
was not associated with AD before (OR=1.02, 95% CI=0.97-1.07;
P
=0.40) and after adjusting for age, sex and APOE ε4 status
(OR=1.00; 95% CI=0.94-1.06;
P
=0.97). In agreement with the previous meta-analysis, Val66Met was associated with AD in
females without confounding adjustment (OR=1.08; 95% CI=1.03-1.14;
P
=0.003). Nevertheless, after adjusting for age and
APOE ε4 status, Val66Met was not associated with AD in either females (OR=1.02; 95% CI=0.94-1.11;
P
=0.57) or males
(OR=0.94; 95% CI=0.86-1.04;
P
=0.22). Likewise, after adjusting for sex and APOE ε4 status, Val66Met was not associated with
AD in either APOE ε4 carriers (OR=0.97, 95% CI=0.88-1.07;
P
=0.56) or non-carriers (OR=1.02, 95% CI=0.94-1.11;
P
=0.64).
This comprehensive meta-analysis with the largest sample size demonstrated no association could be observed between
Val66Met and AD in general or by dividing samples based on sex or APOE ε4.
jiangshan@wustl.edu shannjiang@hotmail.comJ Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C2-040